fiercebiotech.com
Cure8 news brief
Why This Matters
Caldera’s funding and Nasdaq listing mean the company can run phase 2 trials in ulcerative colitis and Crohn’s disease of a bispecific drug that targets two immune pathways. If successful, that approach could change future treatment options for some people with IBD.
Who Should Pay Attention
Adults with IBD (especially those on biologics), patients interested in emerging combination-target therapies, IBD clinicians, and researchers focused on IBD drug development.
Study Snapshot
Story typeBusiness news
Evidence typeMarket or Business News
Source depthFull source text
What To Know
Caldera’s candidate, CLD-423, is a bispecific designed to hit IL-23p19 and TL1A — two pathways that other companies are also pursuing. The company completed phase 1 dosing in healthy volunteers and says the drug was well tolerated; it plans phase 2 programs in ulcerative colitis (global placebo-controlled phase 2b) and an open-label Crohn’s trial in China.
Caldera chose a reverse merger with Synlogic plus a PIPE financing to go public and secure cash into 2029, allowing faster access to capital than a private series B. The article is business-focused: it reports financing, deal terms, and competitive positioning rather than clinical results.
Practical takeaway: This is a financing and development-update story — not new clinical efficacy or safety data in patients. Patients should watch for forthcoming phase 2 data that will better show whether the bispecific adds benefit over current therapies.
Keep In Mind
This article is a biotech business report about a financing and merger; it summarizes company plans and early phase 1 tolerability in healthy volunteers but does not present patient trial results. The candidate is one of several similar bispecific programs in a competitive space, so clinical data will be needed to assess advantage.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationfiercebiotech.com
PublisherFierce Biotech
Indexed viaGoogle News
Source typeWeb article
PublishedJul 29, 2026, 2:34 PM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
J&J Q2 2026: Milvexian timeline, FireFly Bio acquisition, and H2 pipeline catalysts - AllSci
If you have IBD, J&J’s ICOTYDE/TREMFYA‑class program could expand oral IL‑23 treatment options for ulcerative colitis and Crohn’s disease and may have implications for perianal fistulizing Crohn’s disease — an area with...
Biomerica Reports Second Quarter Fiscal 2025 Financial Results
At‑home tests that claim to identify food triggers for IBS or related gut conditions may influence how people manage symptoms. Patents covering tests for Crohn’s and ulcerative colitis suggest the company is aiming to...
Top Biotech Gainers: SNSE Awaits Data In 2H, STTK To Begin Crohn's Trial In Q3, ALMS On Watch
A new Phase 2 Crohn’s trial is planned for Q3 2026 of an investigational DR3‑blocking antibody (SL‑325), which could become a novel treatment approach if later trials show benefit. The report is an investor roundup, so...